Clinical Trials | NRG-GY036 A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy

The University of Virginia seeks adult women with ovarian cancer for a clinical trial. This study compares the effect of a medication called Olaparib, with or without a medication called Bevacizumab, for treatment of BRCA 1/2 mutated or homologous recombination deficient (HRD+) Ovarian cancer. You will be randomized (assigned by chance) to one of two arms - Arm I: You will receive Olaparib orally, twice daily for two years, with or without Bevacizumab intravenously (IV) - Arm II: You will receive Olaparib orally, twice daily for one year, with or without Bevacizumab intravenously (IV) You may be eligible for this study if: - You have stage III or IV ovarian cancer - You have newly diagnosed high grade serous, high grade endometrioid, and/or other epithelial ovarian cancer and BRCA 1/2 deleterious alternation - Are completing previous chemotherapy treatment for your cancer This study involves blood draws and Computed Tomography (CT) scans. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. Additional information can be found here: https://clinicaltrials.gov/study/NCT06580314